12:00 AM
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gemesis bercaplermin regulatory update

EMEA's CHMP issued a final negative opinion on BioMimetic's MAA for Gemesis bercaplermin (GEM 21S) to regenerate tissue in adults with defects around the teeth, including defects within the surrounding bone and receding gums. The decision confirms CHMP's initial negative opinion...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >